Latigo Biotherapeutics (NASDAQ:LTGO) Sets New 1-Year High – Here’s Why

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $25.22 and last traded at $24.99, with a volume of 24875 shares trading hands. The stock had previously closed at $24.13.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th.

Latigo Biotherapeutics Stock Up 6.2%

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, Director James B. Tananbaum purchased 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the director owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.